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Introduction
Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide (1, 2) . Despite advances in the diagnosis and therapy of lung cancer, the overall fiveyear survival rate of patients is still not more than 15%. One promising approach to reduce lung cancer mortality is identification of preneoplastic lesions and administration of chemopreventive agents with the objective of reversing, suppressing or arresting lung tumorigenesis. Mucosal changes in the large airways that precede or accompany lung squamous cell carcinoma (LSCC), the second most common type of lung cancer, include hyperplasia, squamous metaplasia, squamous dysplasia, and carcinoma in situ (3) . Whereas hyperplasia and squamous metaplasia are considered reactive and reversible changes, dysplasias and carcinoma in situ are the changes most frequently associated with the development of LSCC (4) . Thus, chemopreventive agents that inhibit malignant progression of dysplastic or carcinoma in situ lesions could prevent LSCC.
So far, the success of translating preclinical lung cancer chemoprevention studies to the clinic has been poor and there is not a single clinically proven lung cancer chemopreventive agent. One explanation for this could be that the animal models used and the lesions targeted are not representative of the human disease treated in clinical chemoprevention trials. For instance, whereas the majority of the preclinical models develop only lung adenoma/adenocarcinoma which arises peripherally in smaller airways and alveoli, the lesions targeted in almost all clinical lung cancer chemoprevention trials are bronchial preneoplastic lesions that arise centrally and have the potential to develop into LSCC. Moreover, since molecular signatures of lung adenocarcinoma are different from those found in LSCC (5, 6) , chemopreventive agents that show efficacy against lung adenocarcinoma may not be equally effective towards LSCC. To rectify these problems, Wang et al (7) developed N-nitroso-trischloroethylurea (NTCU)-induced mouse model of LSCC, which exhibited similar histopathologic features and keratin staining to human LSCC, therefore providing a valuable preclinical model for LSCC. In lieu of the strong epidemiological evidence that links chronic obstructive pulmonary disease (COPD), the main form of chronic pulmonary inflammation, to a higher risk of lung cancer, in particular LSCC (8) (9) (10) (11) , and the many common signaling pathways involved in chronic inflammation and lung tumorigenesis (12, 13 ), a mouse model of inflammation-driven LSCC would better mirror the human disease.
Here, we report on the role of lipopolysaccharide (LPS)-induced pulmonary inflammation in enhancing NTCU-induced mouse LSCC and the efficacy of diindolylmethane (DIM), one of the breakdown products of indole-3-carbinol, a constituent of Brassica vegetables, to suppress inflammation-driven LSCC in mice. LPS, the major component of the cell wall of Gram-negative bacteria and a potent inflammatory agent, exists in substantial amounts in mainstream and sidestream cigarette smoke (14, 15) and has been shown to induce inflammatory response mimicking COPD in mice (16) . Our studies showed that the incidence of LSCC was significantly higher in mice treated with a combination of NTCU and LPS, as compared to the group treated with NTCU alone, and dietary administration of DIM significantly reduced the incidence of LSCC in NTCU plus LPS-treated mice. Assessment of molecular pathways showed increased activation of inflammatory pathways and higher expression of cell proliferation/survival-related proteins and these effects were modulated by DIM.
Materials and Methods

Chemicals and Reagents
Cancer Research. anti-phospho-Akt, anti-total Akt, anti-phospho-extracellular signal-regulated kinase (ERK), antitotal ERK, anti-phospho-p38, total p-38, anti-Mcl-1, anti-p53, anti-COX2, anti-phospho IκBα, anti-total IκBα, anti-Bax, anti-p-21, anti-PARP, anti-β-actin and goat anti-rabbit IgG secondary antibody were from Cell Signaling Technology (Beverly, MA). Mouse diets (AIN-93G and AIN-93M) were purchased from Harlan Teklad (Madison, WI). These diets are standard diets for lung tumorigenesis studies in A/J mice. The AIN-93G diet, high in protein and fat, was used to support rapid growth of the mice until eight weeks of age. AIN-93G diet was then replaced by AIN-93M diet, a low-protein and low-fat diet, which is recommended for adult maintenance.
Mouse LSCC bioassay
For LSCC bioassay, six weeks-old female A/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME) and housed in the specific-pathogen-free animal quarters of Research Animal Resources, University of Minnesota Academic Health Center. After one week of acclimatization, the mice were randomized into six treatment groups (15 mice/group) as follows: Groups 1, 2, 3 and 4 were vehicle control (5% DMSO and 95% physiological saline), LPS control, NTCU control, and NTCU plus LPS control, respectively. LPS (4 μg/mouse, in 50 μl of physiological saline solution) and NTCU (0.5 mmol/L/mouse in 50 μl of vehicle control, 25 µl in each nostril) were administered intranasally, once a week, on Mondays and Wednesdays, respectively, throughout the study. The vehicle group was given 50 µl physiological saline were maintained on non-supplemented diet. Body weights and food consumption were determined weekly throughout the study. Upon termination of the study at week 26, mice were euthanized with an overdose of carbon dioxide, the lungs harvested and preserved in 10% buffered formalin for histopathological analyses of the tumors. The experimental design of the tumor bioassay is depicted in Fig. 1 .
To harvest lung tissues for Western immunoblotting or qRT-PCR assay, mice (three/group) were treated with vehicle, LPS, NTCU, NTCU plus LPS, and NTCU plus LPS plus DIM as described above. At week 10, lungs tissues were harvested and either kept on dry ice (for immunoblotting assay) or preserved in RNA latter (for qRT-PCR assay) until stored at -80 °C.
The rationale for the short treatment time was that whereas early changes in gene/protein expression could be most likely drivers of the carcinogenesis process, changes in gene/protein expression after formation of the tumors are difficult to interpret as they might be causes or consequences of tumorigenesis. 7 20 sections (approximately 100 μm apart) was stained with Hematoxylin and Eosin and examined under a light microscope. All cross-sectional cuts of bronchioles were counted on all of the slides.
Quantitative RT-PCR (QRT-PCR) analysis of cytokines in mouse lungs
Total RNA was extracted from mouse lung tissues using the miRNeasy Mini Kit (Qiagen, 
STAT3-and NF-κB -DNA binding Assay
To determine if STAT3 and NF-κB binding to DNA is modulated by the different treatments, we used the TransAM transcription factor assay (Active Motif, CA), a non-radioactive transcription factor ELISA kit that facilitate the study of transcription factor activation, and the Odyssey Infrared electrophoretic mobility shift assay (EMSA) Kit (LI-COR, Lincoln, NB), which is an excellent alternative method to radioisotopic and chemiluminescent EMSA detection methods.
Ten µg of nuclear protein extract prepared from mouse lung tissues were diluted in complete lysis buffer and added into each well coated with oligonucleotide containing STAT3 or NF-κB consensus binding site. Under the assay conditions, STAT3 or NF-κB subunit proteins in nuclear extract bind to the oligonucleotide, and STAT3 or p65 was detected by using a primary antibody specific to the proteins followed by incubation with horseradish peroxidase conjugated secondary antibody and colorimetric reading at 450 nm. Wild type consensus oligonucleotide (CO) was used as a competitor to prevent STAT3 or NF-κB binding to the probe immobilized on the plate. In order to monitor the specificity of the assay, nuclear protein extracts (5 µg 
Statistical Analyses
Statistical analyses were performed using one way ANOVA and 2-tailed t-test in Average food consumption per mouse was 2.2 to 2.6 g/day and dietary administration of DIM did not cause ill health effects, nor did it reduce food consumption or body weight gain, indicating that, at the dose level given, the agent is well tolerated.
Since chronic inflammation plays a multifaceted role in tumorigenesis, including initiation, promotion and progression (17), we sought to examine if chronic treatment with the potent inflammatory agent LPS enhances the development of NTCU-induced pulmonary preneoplastic lesions and LSCC in mice. Images of normal bronchial epithelium, bronchial preneoplastic lesions (hyperplasia, metaplasia, carcinoma in situ) and LSCC and the incidence of the lesions in the various groups of mice are depicted in Figs. 2a and 2b, respectively. In mice treated with NTCU alone, the percentages of normal bronchioles, and bronchioles with hyperplasia, metaplasia, carcinoma in situ and LSCC were 57.8 ± 8.8%, 37.8 ± 5.7%, 0.3 ± 0.4%, 1.2 ± 1.2% and 3.8 ± 2.9%, respectively. Upon dietary administration of DIM, only the incidence of hyperplastic lesions was significantly modulated (increased by 28%). Compared to the group treated with NTCU alone, in mice treated with NTCU plus LPS, the percentage of normal bronchioles decreased by about 2-fold (24.3 ± 17.7% versus 56.8 ± 8.8%) , whereas that of LSCC increased by about 9-fold (28.8 ± 15.4% versus 3.8 ± 2.9%). Dietary administration of DIM to mice treated with NTCU plus LPS slightly increased the percentage of normal bronchi and bronchial hyperplasia (30.4 ± 7.4% versus 24.3 ± 7.7% and 54.0 ± 9.0% versus 44.5 ± 9.4%, respectively), but decreased the incidence of carcinoma in situ (0.9 ± 1.0% versus 2.4 ± 2.8%) 
and LSCC (14.6 ± 5.5% versus 28.8 ± 5.4%). However, only the effect of DIM on LSCC was statistically significant. Mice treated with vehicle control (physiological saline) or LPS alone did not exhibit any abnormal lesion.
Combinatory treatment with NTCU and LPS enhanced the expression of inflammatory cytokines.
Inflammation is mediated by a variety of soluble factors, including cytokines and therefore we compared the expression of different cytokines among the various treatment groups.
These results are shown in Table 2 Combinatory treatment with NTCU and LPS activated inflammatory pathways and these effects were suppressed by DIM.
Components of the inflammatory pathway, including NF-κB, STAT3, and COX-2 play major roles in enhancing tumorigenesis (18) (19) (20) 
LPS, alone or in combination, modulate the level of these proteins and whether dietary administration of DIM suppresses these effects.
To examine the effect of NTCU and LPS, alone or in combination, on the NF-κB pathway, we assessed, by Western immunoblotting, the level of total and phosphorylated IκBα, whose phosphorylation by IκB kinase results in activation and nuclear translocation of NF-κB.
Compared to the group treated with vehicle, neither LPS alone nor NTCU alone significantly modulated the level of total IκBα or phospho-IκBα (Figs. 3a and 3b) . total STAT3. DIM restored these changes to the level in the vehicle control (Figs. 3a and 3b) .
Likewise, in ELISA-based EMSA assays, the combination of NTCU and LPS significantly increased STAT3-DNA binding by more than 2-fold and DIM reversed STAT3-DNA binding to the level measured in the vehicle control group (Fig. 3d) .
Among MAPK proteins, ERK phosphorylation was increased by LPS and NTCU, alone and in combination. However, only the effect of NTCU was significant. On the other hand, the level of p38 phosphorylation was increased 5-fold upon treatment with NTCU alone or LPS alone and 12-fold by the combination of NTCU and LPS. DIM almost completely reversed NTCU plus LPS-induced p38 phosphorylation (Figs. 3a and 3b) .
Combinations of NTCU and LPS increased levels of phospho-Akt and p53 and DIM suppressed the effect on phosphor-Akt.
Alterations in the expression of Akt (21-24) and p53 (25) (26) (27) 
Discussion
In the present study, we showed that LPS, a potent inflammatory agent contained in tobacco and tobacco smoke (14, 15) enhanced LSCC induced by NTCU, a halogenated nitrosoalkylurea, and these effects were paralleled by significant induction of inflammatory cytokines, activation of pro-inflammatory and pro-oncogenic NF-κB and STAT3 signaling pathways and overexpression of p53 and phospho Akt. In mice treated with NTCU alone, only the incidence of bronchial hyperplasia, a reactive and reversible change, was significantly Animal models of inflammation driven-LSCC are highly needed for a thorough understanding of the molecular links between chronic inflammation and LSCC and to identify safe and effective chemopreventive agents. Since tobacco smoking has a stronger association with LSCC than other non-small cell lung cancers (9) (10) (11) and it is also the main cause of COPD (28), a risk factor for LSCC, tobacco smoke appears to be the most ideal agent to induce inflammation-driven LSCC in animal models. However, earlier studies in mice showed that tobacco smoke induces only the adenocarcinoma histological subtype of lung cancer (29, 30) . On the other hand, NTCU has been consistently shown to induce LSCC in mice when administered topically at a dose of 40 mmol/L, (7, (31) (32) (33) (34) . In the present study, in order to develop a mouse model of inflammation-driven LSCC that closely resembles human LSCC, mice were treated with a lower dose of NTCU (about 100-fold lower than the dose used in previous studies) and a COPD-like air way inflammation was induced via repetitive exposure to LPS. Previous studies with mice have shown that LPS-induced inflammatory and pathologic changes closely mimic those observed in human COPD (35, 36) and repetitive exposure of NNK-pretreated mice to LPS doubled lung tumor multiplicity, markedly increased tumor size and increased peritumoral accumulation of macrophages (37) . In the present study, combinatory treatment with a lower dose of NTCU (0.5 mmol/L, about 100-fold lower than the dose used in previous studies) and LPS was as potent as or even more potent than the standard dose of NTCU (40 mmol/L) (29, 30) in inducing LSCC. The higher potency of NTCU plus LPS to induce LSCC could be ascribed partly to the direct delivery of the agents to the lung, the target organ, and partly to the tumor initiating/promoting effects of LPS-induced pulmonary inflammation. 
autoimmune disease or obesity (38) . Molecular mechanisms through which chronic inflammation induces cancer include aberrant inflammatory cytokine and chemokine expression, activation of NF-κB and STAT3 signaling pathways and increased COX-2 (39) . In the present study, whereas administration of LPS or NTCU alone caused a small increase in the expression of inflammatory cytokines, combinatory treatment with NTCU and LPS hugely increased the expression of most cytokines, in particular, IL-6 and TNFα (30-and 21-fold increase). TNFα and IL-6 are few of the best characterized cytokines regarding their protumourigenic effects and their involvement in cancer is owing to their ability to activate the oncogenic transcription factors NF-κB (TNFα) and STAT3 (IL-6) in epithelial cells (40) (41) (42) . TNFα is secreted by several types of cells, including epithelial and inflammatory cells, and once released, it binds to TNF receptor (TNFR) superfamily proteins and activates NF-κB , activator protein-1 (AP-1), and MAPK p38 and ERK 1/2, which, cooperatively, induce a variety of inflammatory genes, including COX-2 and inducible nitrogen oxide synthase (41, 43) . Similarly, IL-6 binds to the gp130/IL6R heterodimeric receptor and activates the Janus kinase/STAT3 signaling pathway (44) . In line with the above reports, combinatory treatment with NTCU and LPS, parallel to significant induction of TNFα and IL-6, activated NF-κB, STAT3, MAPK p38 and ERK1/2, enhanced NF-κB-and STAT3-DNA binding, and increased expression of COX-2. Assuming A/J mice (25 g body weight) consume 2.5 g diet per day, the dose of DIM used in the present study (10 µmol/g diet) would be equivalent to 250 mg/kg body weight. Using allometric scaling, this translates to a dose of about 1, 400 mg/day for a 70 Kg human. However, the calculated human dose might have been overestimated given the inaccuracies in mouse food consumption measurements. In a recent clinical trial (49), DIM was administered at a dose of 300 mg twice daily (total daily dose of 600 mg) and found to be well tolerated.
In conclusion, in the present study, we showed that combinatory treatment with NTCU and LPS caused in mice a higher incidence of LSCC than NTCU alone and this effect was 
